#1Pending#2Pending#3Pending#4Company overview Financial review 2022 priorities Appendix References Novartis delivers solid Q2 performance across our value drivers Growth, cc Group sales Q2 +5% (H1 +5%) IM sales Q2 +5% (H1 +5%) Sandoz sales Q2 +5% (H1 +6%) 1 Innovation CosentyxⓇ childhood arthritic conditions approved in EU KymriahⓇ r/r FL approved in US and EU ScemblixⓇ Ph+ CML received positive CHMP opinion 3 Productivity, cc Group core operating income Q2 +5% (H1 +7%) IM core operating income Q2 +6% (H1 +6%) IM core margin Q2 37.2%, +0.5%pts (H1 36.6%) Sandoz core operating income Q2-4% (H1 +10%) SG&A savings expected to increase to ~USD 1.5bn by 2024 2 ESG 4 Innovation NTDs: USD 250m R&D investment over 5 years (Kigali declaration) Innovation CT diversity: >USD 50m commitment over 10 years (Beacon of Hope) MSCI upgrades Novartis to AA: Now top quartile within the industry Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 47 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. division r/r FL - relapsed or refractory follicular lymphoma GVHD - acute and chronic graft-versus-host disease CML - chronic myeloid leukemia NTDs - Neglected tropical diseases CT Clinical trial 4 Investor Relations | Q2 2022 Results IM - Innovative Medicines ✓ NOVARTIS | Reimagining Medicine#5Pending#6Pending#7Pending#8Company overview Financial review 2022 priorities Appendix References CosentyxⓇ double digit demand-driven growth in Q2 Sales evolution USD m, % cc Ex-US US 1,175 +12% 1,275 539 460 715 736 Q2 2021 Q2 2022 1 GROWTH Cosentyx E AZ K KL Maintaining double-digit growth outlook for FY2022 Steady volume growth across US, EU and China Confidence in clinical profile; >700k patients across 5 indications GRAPPA PSA guidelines highlight Cosentyx unique benefit in axial manifestations and proven efficacy of IL17 across all 6 domains¹ Confident in USD 7bn+ peak sales Continued demand-led growth WW Life cycle management - Q2 progress: - JPSA/ ERA pediatric approvals in EU - HS submitted in EU, US anticipated H2 - axSpA IV study (INVIGORATE 2) positive readout - PSA IV US submission anticipated H2 WW Worldwide HS - Hidradenitis Suppurativa JPSA - Juvenile Psoriatic Arthritis ERA - Enthesitis related arthritis PSA - Psoriatic Arthritis axSpA - axial Spondyloarthritis Assessment of Psoriasis and Psoriatic Arthritis 1. Coates et al. Nat Rev Rheumatol (2022) IV Intra venous GRAPPA - Group for Research and 8 Investor Relations | Q2 2022 Results ✓ NOVARTIS | Reimagining Medicine#9Company overview Financial review 2022 priorities Appendix References Entresto® +33% cc, growing strongly across geographies Sales evolution USD m, % cc Ex-US US 00 8 +33% 7 1,125 6 886 577 5 481 548 405 Q2 2021 Q2 2022 2 4 US weekly NBRx1 New-to-brand prescriptions (000) 03/20 05/20 07/20 09/20 11/20 01/21 03/21 05/21 07/21 09/21 11/21 01/22 03/22 05/22 07/22 1 GROWTH C Entresto AZ K&K L Strong quarter performance " Worldwide >7m patients treated, US >1m TRX US growing in hospitals, cardiology, primary care¹ Europe strong demand growth Asia HTN driving growth Confident in future growth ■ Only 1/3 of addressable HF population treated in G72 Strong profile in clinical and RW settings in HF3,4 Guidelines drive 1st choice in HFrEF and expand support in HFPEF w/LVEF < normal 5 HTN: high unmet need in Asia See last slide for references TRX Total Prescriptions NBRX-New-to-brand Prescriptions RW Real world HFrEF-heart failure with reduced ejection fraction HFPEF-heart failure with preserved ejection fraction HTN - Hypertension LVEF - left ventricular ejection fraction 9 Investor Relations | Q2 2022 Results ✓ NOVARTIS | Reimagining Medicine#10Pending#11Pending#12Company overview Financial review 2022 priorities Appendix References 1 GROWTH Strong Kesimpta®Ⓡ launch continues, outperforming market CEZ K Kesimpta L Sales evolution USD m, % cc Ex-US US 99 66 50 147 109 +24% 239 195 Q1/21 Q2/21 Q3/21 Q4/21 Q1/22 Q2/22 Launch acceleration continues Increasing real-world experience with >20k patients treated WW US demand +18% QoQ, >3,200 adopters since launch NBRX +42% YoY vs. US NBRx market -12%1 Strengthening differentiation and benefit/risk profile New extension phase data: 8/10 patients treated continuously with KesimptaⓇ had no evidence of disease activity (NEDA-3)² Fast initiation within 6 days for 80% patients³ 77% of patients remain on therapy at 12 months4 See last slide for references WW-worldwide NBRX - New to brand Prescription NEDA - No Evidence of Disease Activity 12 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#13Pending#14Pending#15Company overview Financial review 2022 priorities Appendix References ScemblixⓇ continues strong US uptake and achieves important ex-US regulatory milestones in Q2 1 GROWTH Strong early launch uptake Confident in future growth ✓ $31m Q2 sales driven by patients with resistance/intolerance to other TKIs 1L WW Ph3 study enrolling ahead of plan 44% 3L+ new patient share¹ CHMP positive opinion and rollout ongoing across ex-US markets 16% NBRx share across CML lines of treatment¹ 1. Source: IQVIA Market Sizing "Source of Business", "Product Summary" reports, June 2022 15 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#16Pending#17Company overview Financial review 2022 priorities Appendix References Broad pipeline of novel medicines continued to progress in Q2 Hematology Solid tumors Immunology Neuroscience Cardiovascular Approvals TabrectaⓇ TafinlarⓇ+ MekinistⓇ JakaviⓇ KymriahⓇ EU: adv. non-small cell lung cancer US: tumor-agnostic for BRAF V600E solid tumors EU: acute and chronic GVHD Readouts and publications icenticaftor sabatolimab Ph2 - COPD¹ CosentyxⓇ Ph2-HR-MDS STIMULUS MDS-1 Ph3-axSpA IV INVIGORATE US and EU: r/r follicular lymphoma Cosentyx® Submissions Ph2 lichen planus PRELUDE³ BeovuⓇ CosentyxⓇ US and JP: diabetic macular edema EU: JPSA & ERA CosentyxⓇ adalimumab EU: hidradenitis suppurativa EU 3 INNOVATION 2 Designations and milestones ScemblixⓇ pelacarsen JDQ443 EU positive CHMP for CML 3L Ph3 HORIZON recruitment completed Ph3 2/3L NSCLC initiated Selected milestones 1. Ph2b DRF demonstrated dose response across multiple endpoints, study results presentation end 2022 Biosimilar Exiting development projects: COPD, general asthma CSJ117 icenticaftor Decision to partner Decision to partner 2. Submission will be based on Ph3 results 3. Data analysis on-going 17 Investor Relations | Q2 2022 Results ✓ NOVARTIS | Reimagining Medicine#18Company overview Financial review 2022 priorities Appendix References KisqaliⓇ is the only CDK4/6i with consistent OS benefit seen across all three Ph3 trials KisqaliⓇ Ph3 OS results in 1L MBC KisqaliⓇ unique in inhibiting CDK4 8x more than CDK67-10 MONALEESA-2 Median OS Risk reduction 24% 63.9 months1 MONALEESA-7 Risk reduction 24% 58.6 months² MONALEESA-3 Risk reduction 33% 67.6 months3 Unbound Cavg relative to palbo 19x 16x 13x 10x 7x 4x Palbociclib 1x T Abemaciclib NATALEE adjuvant study on track NATALEE study design 3 INNOVATION RIB+ Ribociclib 400mg/day 3 weeks on/1 week off 36 months (-39 cycles) 36 months NSAI 60 months 60 months [+goserelin in pre-menopausal women & men] Ribociclib HR HER2-eBC Pre- and post- menopausal ET R 1:1 Anatomic Stage II & III 1x 2x 3x 4x 5x 6x 7x 8x CDK4:CDK6 inhibition from a cellular assay N=5000 NSAI 60 months 60 months [+goserelin in pre-menopausal women & men] " Longest median OS benefit ever published 4 ■ Same OS benefit regardless of menopausal status, hormone therapy partner, or dose modifications5 Maintains clinical benefit even after prior CDK4/6i use6 ■ At clinically relevant doses, KisqaliⓇ provides greater CDK4 inhibition in vivo than competitors Higher unbound Cavg means more drug available to act on tumor cells 7-10 Fully enrolled as of April 2021 Primary analysis planned at 500 iDFS events, expected in 2023 ■ Interim analyses at 70% and 85% See last slide for other references 1. In months vs. vs 51.4, P value: 0.008. Reference: Hortobagyi, GN et al., 2022 2. vs 51.8. Reference: Lu, YS et al., 2022 3. vs 51.4. Reference: Neven, P et al., 2022 4. for HR+/HER2- MBC 18 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#19Pending#20Company overview Financial review 2022 priorities Appendix References Harry Kirsch Chief Financial Officer Financial review and 2022 guidance 20 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#21Pending#22Pending#23Company overview Financial review 2022 priorities Appendix References 2022 full year guidance Expected, barring unforeseen events; growth vs. PY in cc Innovative Medicines Sales to grow mid single digit Core Oplnc to grow mid to high single digit, ahead of sales Sales to grow low single digit (revised upwards from broadly in line) Sandoz Core Oplnc to be broadly in line with prior year (revised upwards from to decline low to mid single digit) Sales to grow mid single digit Group Core Oplnc to grow mid single digit Key assumptions Our guidance assumes that we see a continuing return to normal global healthcare systems, including prescription dynamics, and that no GilenyaⓇ and no SandostatinⓇ LAR generics enter in the US. In June 2022, an appeals court held the Gilenya US dosing regimen patent invalid. Novartis plans to petition the appeals court for further review to uphold validity of the dosing regimen patent. There is no generic competition in the US at this time. In Q2, Gilenya US sales were USD 332m, US sales have been steadily declining due to competitive pressures. 23 Investor Relations | Q2 2022 Results 1 NOVARTIS | Reimagining Medicine#24Pending#25Company overview Financial review 2022 priorities Appendix References Simplified organizational model: SG&A savings estimate increased to ~USD 1.5bn fully embedded by 2024 Estimated annual savings Illustrative 2022 Minimal impact, offsetting energy costs and inflation pressure in supply chain 25 Investor Relations | Q2 2022 Results ~USD 1.5bn 2023 2024 One-time restructuring cost now estimated at 1 to 1.2x annual structural savings Integrated Operations unit synergies Simplification of M&S structure (non-customer-facing) Streamlining G&A functions The savings will contribute to achieving mid-long term IM core margins in the low 40's and investing in our pipeline NOVARTIS | Reimagining Medicine#26Pending#27Company overview Financial review 2022 priorities Appendix References We remain disciplined and shareholder-focused in our capital allocation H1 2022 updates Investing in the business Returning to shareholders Investments in organic business USD 4.5bn R&D¹ USD 0.5bn capital investments Capital allocation Growing annual dividend in CHF USD 7.5bn paid out Value-creating bolt-ons USD 0.9bn 1. Core R&D actuals 2022 27 Investor Relations | Q2 2022 Results priorities Share buybacks USD 9.4bn to be executed USD 5.6bn completed of the USD 15bn 1 NOVARTIS | Reimagining Medicine#28Pending#29Pending#30Company overview Financial performance Financial review Appendix 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials References Abbreviations 30 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#31Pending#32Pending#33Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Appendix Innovation: Clinical trials reinforcing our confidence in mid-term growth outlook H1 sales Cosentyx USD 2.4 bn +12% Entresto zolgensma® KISQALI USD 2.2 bn USD 0.7 bn USD 0.5 bn +37% +22% +36% References Abbreviations CE K KL Kesimpta LEQVIO® USD 0.4 bn 280% nm nm Peak sales USD >7bn US LOE 2029+ Peak sales USD >5bn US LOE 2025-2036 Peak sales multi-bn¹ US LOE 2031+ Peak sales multi-bn US LOE 2031+ Peak sales multi-bn US LOE 2031+ nm not meaningful. All growth rates in constant currencies (cc). US LoEs are estimated based on relevant patents; further extensions possible. 1. Including Zolgensma® IT. 33 Investor Relations | Q2 2022 Results Peak sales multi-bn US LOE 2036+ U NOVARTIS | Reimagining Medicine#34Pending#35Company overview Financial performance Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials References Abbreviations Net debt increased by USD 8.6bn mainly due to the annual dividend payment and share buybacks (USD bn) -0.9 -7.5 -0.9 -8.6 -9.5 0.8 -5.2 4.2 Dec 31, 2021 Dividends M&A transactions Treasury share transactions, net Free Cash Flow Others June 30, 2022 35 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#36Pending#37Pending#38Pending#39Pending#40Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis pipeline in Phase 2 Solid Tumors Code Name AAA601 LutatheraⓇ DRB436 Tafinlar® + Mekinist® JDQ443 JDQ443 NIR178 NIR178, spartalizumab NIS793 NIS793 TNO155 TNO155 Ad2AR inhibitor, PD1 inhibitor TGFB inhibitor Mechanism Indication(s) Radioligand therapy target SSTR GEPNET, pediatrics BRAF inhibitor + MEK inhibitor KRAS inhibitor 1L ES-SCLC Glioblastoma HGG/LGG, pediatrics NSCLC (Combo) Cancers 1L metastatic colorectal cancer SHP2 inhibitor Solid tumors (single agent) Hematology Appendix Innovation: Clinical trials References Abbreviations 27 lead indications Lead indication Code ABL001 Name ScemblixⓇ INC424 JakaviⓇ LNP023 iptacopan MBG453 sabatolimab PHE885 PHE885 PKC412 Rydapt® Mechanism BCR-ABL inhibitor JAK1/2 inhibitor CFB inhibitor TIM3 antagonist BCMA cell therapy Multi-targeted kinase inhibitor Indication(s) Chronic myeloid leukemia, 2L, pediatrics Acute GVHD, pediatrics Immune thrombocytopenia Unfit acute myeloid leukaemia Acute myeloid leukaemia, maintenance 4L multiple myeloma Acute myeloid leukemia, pediatrics Chronic GVHD, pediatrics Cardio-renal Mechanism CD40 inhibitor Indication(s) Lupus nephritis Type 1 diabetes mellitus Atrial fibrillation Membranous nephropathy Obesity related diseases. Immunology Code Code Name Mechanism Indication(s) AIN457 CFZ533 Cosentyx® iscalimab IL17A inhibitor CD40 inhibitor Lichen planus Sjögren's Liver Tx Hidradenitis suppurativa Name CFZ533 iscalimab HSY244 HSY244 LNP023 iptacopan MBL949 MBL949 CFB inhibitor CMK389 CMK389 DFV890 DFV890 IL-18 inhibitor NLRP3 inhibitor LNA043 LNA043 ANGPTL3 agonist Atopic dermatitis Familial cold auto-inflammatory syndrome Knee osteoarthritis Osteoarthritis (combos) Osteoarthritis Name Mechanism LOU064 remibrutinib LRX712 LRX712 BTK inhibitor Sjögren's Osteoarthritis Anti-inflammatory Acne Colitis ulcerative NLRC4-GOF indications Hidradenitis suppurativa Hidradenitis suppurativa LYS006 LYS006 MAS825 MAS825 MHV370 MHV370 VAY736 ianalumab BAFF-R inhibitor Neuroscience Code Name ADPT06 ADPT06 sotuletinib Mechanism BLZ945 CSF-1R inhibitor DLX313 LMI070 DLX313 (UCB0599) branaplam Alpha-synuclein Inhibitor mRNA splicing modulator MIJ821 MIJ821 NR2B negative allosteric modulator 1. Gyroscope acquisition Sjögren's Sjögren's Systemic lupus erythematosus Indication(s) Cognitive impairment Amyotrophic lateral sclerosis Parkinson's disease Huntington's disease Mixed connective tissue disease Autoimmune hepatitis Major depressive disorder with acute suicidal ideation or behavior Others Code Global Health KAE609 cipargamin KAF156 ganaplacide LXE408 LXE408 SEG101 Adakveo® Respiratory & Allergy CMK389 CMK389 QBW251 icenticaftor QMF149 AtecturaⓇ Ophthalmology LKA651 LKA651 PPY9881 PPY988 SAF312 libvatrep UNR844 UNR844 PfATP4 inhibitor Proteasome inhibitor P-selectin inhibitor IL-18 inhibitor CFTR potentiator Combo EPO inhibitor Gene therapy TRPV1 antagonist Reduction of disulfide bonds Indication(s) Malaria, severe Malaria, uncomplicated Visceral leishmaniasis Malaria, uncomplicated Sickle cell disease, pediatrics Pulmonary sarcoidosis Chronic obstructive pulmonary disease Bronchiectasis Asthma, pediatrics Diabetic retinopathy Geographic atrophy Chronic ocular surface pain Presbyopia 40 Investor Relations | Q2 2022 Results U NOVARTIS | Reimagining Medicine#41Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis pipeline in Phase 3 Solid Tumors Hematology Appendix Innovation: Clinical trials References Abbreviations 8 lead indications Lead indication Mechanism BCR-ABL inhibitor CD19 CAR-T Thrombopoietin receptor (TPO-R) agonist CFB inhibitor Indication(s) Chronic myeloid leukemia, 1st line 1L high risk acute lymphocytic leukaemia, pediatrics & young adults Radiation sickness syndrome Paroxysmal nocturnal haemoglobinuria Atypical haemolytic uraemic syndrome Myelodysplastic syndrome 2L Diffuse large B-cell lymphoma4) Code AAA617 Name Mechanism Indication(s) Code Name PluvictoⓇ Radioligand therapy target PSMA mCRPC, pre-taxane ABL001 Scemblix AAA6011) Lutathera® Metastatic hormone sensitive prostate cancer (mHSPC) Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3 tumors (GEP-NET 1L G3) CTL019 ETB115 KymriahⓇ Promacta® ACZ885 canakinumab IL-1b inhibitor NSCLC, adjuvant LNP023 iptacopan BYL719 JDQ443 Piqray® JDQ443 PI3Ka inhibitor HER2+ adv BC Triple negative breast cancer Ovarian cancer KRAS inhibitor 2/3L Non-small cell lung cancer MBG453 sabatolimab YTB323 YTB323 TIM3 antagonist CD19 CAR-T LEE011 Kisqali® CDK4 Inhibitor NIS793 NIS793 TGFB1 inhibitor VDT482 Tislelizumab PD1 inhibitor HR+/HER2- BC (adj) 1L Nasopharyngeal Carcinoma 1L ESCC 1L Metastatic pancreatic ductal adenocarcinoma Adj/Neo adj. NSCLC Immunology Code 1L Hepatocellular Carcinoma 1L Gastric cancer Localized ESCC 1L Urothelial Cell Carcinoma 1L Small Cell Lung Cancer AIN457 Name Cosentyx® Mechanism IL17A inhibitor IgE inhibitor LOU064 remibrutinib QGE031 ligelizumab VAY736 ianalumab BTK inhibitor BAFF-R inhibitor Indication(s) Lupus Nephritis Psoriatic arthritis (IV formulation) Axial SpA (IV formulation) Giant cell arteritis Chronic spontaneous urticaria Food allergy Lupus Nephritis³) Neuroscience Code Name AMG334 AimovigⓇ BAF312 MayzentⓇ LOU064 remibrutinib OAV101 AVXS-101 OMB157 KesimptaⓇ Mechanism CGRPR antagonist S1P1,5 receptor modulator BTK inhibitor Indication(s) Migraine, pediatrics Multiple sclerosis, pediatrics Multiple sclerosis SMN1 gene replacement therapy SMA IT administration CD20 Antagonist Multiple sclerosis, pediatrics 1. 177 Lu-dotatate in US 2. Approved in US 3. Ph3 initiating 4. Ph3 to be initiated pending strategy update 41 Investor Relations | Q2 2022 Results Cardio-renal Code Name KJX839 Leqvio® LCZ696 EntrestoⓇ Mechanism siRNA (regulation of LDL-C) Angiotensin receptor/neprilysin inhibitor LNP023 iptacopan CFB inhibitor TQJ230 Pelacarsen ASO targeting Lp(a) Indication(s) CVRR-LDLC Hyperlipidemia, pediatrics Congestive heart failure, pediatrics²) IgA nephropathy C3 glomerulopathy Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a) (CVRR-Lp(a)) Others Code Name Mechanism Global Health COA566 Coartem® Respiratory & Allergy IGE025 Xolair® IgE inhibitor Ophthalmology RTH258 BeovuⓇ Biosimilars Code Name GP2411 denosumab SOK583 aflibercept Indication(s) VEGF inhibitor Malaria, uncomplicated (<5kg patients) Food allergy Diabetic retinopathy Auto-injector Mechanism anti RANKL mAb VEGF inhibitor Indication(s) Osteoporosis (same as originator) Ophthalmology indication (as originator) U NOVARTIS | Reimagining Medicine#42Pending#43Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis submission schedule New Molecular Entities: Lead and supplementary indications LEAD INDICATIONS Appendix Innovation: Clinical trials References Abbreviations 2022 2023 2024 2025 ≥2026 ensovibep Lead SKO136 COVID19 iptacopan LNP023 PNH Lead JDQ443 JDQ443 Lead icenticaftor³ Lead 177 Lu-NeoB Lead iscalimab Lead QBW251 AAA603 CFZ533 MIJ821 Acute depression Lead 2/3L NSCLC (mono) COPD Multiple Solid Tumors Sjögren's syndrome sabatolimab Lead ligelizumab Lead branaplam Lead ianalumab Lead PPY9882 Lead MBG453 QGE031 LMI070 VAY736 Geographic atrophy HR-MDS Food allergy Huntington's disease Sjögren's syndrome remibrutinib Lead NIS793 Lead cipargamin Lead libvatrep Lead TNO155 Lead 1L Pancreatic cancer KAE609 SAF312 Solid tumors LOU064 Malaria severe COSP CSU UNR844 Presbyopia Lead pelacarsen Lead ganaplacide Lead LNA043 Lead TQJ230 KAF156 Knee osteoarthritis CVRR-Lp(a) Malaria uncomplicated YTB3231 Lead gevokizumab Lead LXE408 Lead 2L Diffuse large B-cell lymphoma VPM087 Visceral leishmaniasis 1st line CRC tislelizumab LCM Pluvicto LCM Pluvicto LCM Scemblix LCM cipargamin LCM ianalumab LCM Scemblix LCM AAA617 ABL001 KAE609 VAY736 ABL001 VDT482 AAA617 NEW INDICATIONS 1L Nasopharyngeal Carcinoma mCRPC, Pre-taxane MHSPC CML 1L Malaria uncomplicated SLE CML, 2L, pediatrics tislelizumab LCM iptacopan LCM tislelizumab LCM VDT482 LNP023 VDT482 NSCLC C3G 1L Small Cell Lung Cancer iptacopan LNP023 aHUS LCM JDQ443 LCM iscalimab LCM remibrutinib LCM JDQ443 CFZ533 LOU064 NSCLC (combo) Liver Tx Sjögren's syndrome iptacopan LCM remibrutinib LCM ianalumab LCM iptacopan LCM tislelizumab LCM LNP023 LOU064 VAY736 LNP023 VDT482 IgAN Multiple sclerosis АІН iMN Adj/Neo adj NSCLC tislelizumab LCM ianalumab LCM sabatolimab LCM tislelizumab LCM VAY736 MBG453 VDT482 VDT482 Unfit AML 1L Gastric Cancer Lupus Nephritis 1L Urothelial Cell Carcinoma tislelizumab LCM VDT482 1L ESCC tislelizumab LCM VDT482 Localized ESCC tislelizumab LCM VDT482 1L Hepatocellular Carcinoma 1. Development strategy being updated 2. Gyroscope acquisition 3. Out-licensing planned 43 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#44Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis submission schedule Supplementary indications for existing brands Appendix Innovation: Clinical trials References Abbreviations 2022 2023 2024 2025 Cosentyx LCM canakinumab LCM aflibercept BioS Beovu LCM Atectura LCM secukinumab, AIN457 ACZ885 SOK583 PSA IV Adjuvant NSCLC Neovascular age-related macular degeneration brolucizumab, RTH258 Diabetic retinopathy indacaterol + mometasone, QMF149 Asthma, pediatrics ≥2026 Kesimpta³ ofatumumab LCM Mayzent³ LCM siponimod, BAF312 Multiple sclerosis, pediatrics Multiple sclerosis, pediatrics Cosentyx LCM Cosentyx LCM Adakveo LCM Cosentyx LCM Aimovig LCM Kymriah LCM Piqray LCM secukinumab, AIN457 secukinumab, AIN457 SEG101 secukinumab, AIN457 erenumab, AMG334 tisagenlecleucel, CTL019 alpelisib, BYL719 Hidradenitis suppurativa axSpA IV Sickle cell disease, pediatrics GCA Pediatric Migraine 1L high risk ALL, pediatrics & young adults TNBC Entresto EU1 LCM denosumab BioS Coartem LCM Cosentyx LCM Cosentyx LCM Leqvio LCM Rydapt LCM sacubitril/valsartan, LCZ696 GP2411 Pediatric CHF anti RANKL mAb artemether + lumefantrine, COA566 Malaria uncompl., formula for <5kg secukinumab, AIN457 Lichen Planus secukinumab. AIN457 Lupus Nephritis KJX839 midostaurin, PKC412 CVRR-LDLC Acute myeloid leukemia, pediatrics Tafinlar + Mekinist LCM Kisqali LCM Jakavi LCM Leqvio LCM dabrafenib + trametinib, DRB436 ribociclib, LEE011 ruxolitinib, INC424 KJX839 HGG/LGG - Pediatrics. HR+/HER2- BC (adj) Pediatrics Acute GVHD Ped Hyperlipidemia Xolair LCM Lutathera LCM Jakavi LCM Piqray LCM omalizumab, IGE025 177Lu-oxodotreotide² ruxolitinib, INC424 alpelisib, BYL719 Auto-injector GEP-NET 1L G3 Pediatrics Chronic GVHD HER2+ adv BC Piqray LCM Promacta LCM alpelisib, BYL719 eltrombopag, ETB115 Ovarian cancer Radiation sickness syndrome Xolair LCM Zolgensma LCM omalizumab, IGE025 AVXS-101 OAV101 Food allergy SMA IT 1. Approved in US. 2. 177Lu-dotatate in US. 3. Kesimpta and Mayzent: pediatric study in multiple sclerosis run in conjunction (NEOS). 44 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#45Company overview Financial performance Oncology Financial review 2022 priorities Innovation: Pipeline overview Immunology Ophthalmology Appendix Innovation: Clinical trials Neuroscience Respiratory Disease Clinical Trials Update Includes selected ongoing or recently concluded global trials of Novartis development programs/products which are in confirmatory development or marketed (typically Phase 2b or later). For further information on all Novartis clinical trials, please visit: www.novartisclinicaltrials.com References Abbreviations Cardio-Renal Global Health Biosimilars 45 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#46Pending#47Pending#48Pending#49Pending#50Pending#51Company overview Financial performance Oncology Immunology Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Ophthalmology Neuroscience Respiratory Disease JDQ443-KRAS inhibitor NCT05132075 KontRASt-02 (CJDQ443B12301) Indication Non-small cell lung cancer, 2/3L Phase Phase 3 Patients 360 Primary Outcome Measures Arms Progression free survival (PFS) Intervention Target Patients Read-out Milestone(s) Arm 1 Experimental: JDQ443 Arm 2 Active Comparator: Participant will be treated with docetaxel following local guidelines as per standard of care and product labels Patients with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum- based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination. 2024 Publication NA References Abbreviations Cardio-Renal Global Health Biosimilars 51 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#52Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars KisqaliⓇ - CDK4/6 inhibitor NCT03701334 NATALEE (CLEE011012301C) Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Adjuvant treatment of hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC) Phase 3 5101 Invasive Disease-Free Survival for using STEEP criteria (Standardized Definitions for Efficacy End Points in adjuvant breast cancer trials) Ribociclib endocrine therapy Endocrine therapy Pre and postmenopausal women and men with HR-positive, HER2-negative EBC, after adequate surgical resection, who are eligible for adjuvant endocrine therapy Read-out Milestone(s) 2023 Publication TBD 52 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#53Pending#54Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars NIS793 - TGFẞ1 inhibitor NCT04935359 daNIS-2 (CNIS793B12301) Indication Phase 1L metastatic pancreatic ductal Adenocarcinoma Phase 3 Patients 501 Primary Outcome Measures Arms Intervention Safety run-in part: Percentage of participants with dose limiting toxicities (DLTs) during the first cycle (4 weeks) of treatment Randomized part: Overall survival (OS) Safety run-in part: NIS793+gemcitabine+nab-paclitaxel Randomized portion of the study: Arm 1: NIS793+gemcitabine+nab-paclitaxel Arm 2: placebo+gemcitabine+nab-paclitaxel Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), first line treatment Target Patients Read-out Milestone(s) Publication NA Primary: 2024 54 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#55Pending#56Pending#57Pending#58Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars PromactaⓇ - Thrombopoetin receptor agonist PromactaⓇ - Thrombopoetin receptor agonist NCT03025698 (CETB115E2201) Refractory or relapsed severe aplastic anemia Indication Phase Phase 2 Patients 51 Primary Outcome Measures Arms Intervention Target Patients Read-out NCT03988608 (CETB115E2202) Indication Phase Refractory or relapsed severe aplastic anemia Phase 2 Patients 20 PK of eltrombopag at steady state in pediatric patients with SAA Primary Outcome Eltrombopag 12.5, 25, 50, 75 mg FCT & 25 mg pFOS Arm A: relapsed/refractory SAA or recurrent AA following IST for SAA: hATG/cyclosporine + eltrombopag or cyclosporine + eltrombopag Arm B: previously untreated SAA: hATG/cyclosporine + eltrombopag Pediatric patients from age 1 <18 years with relapsed/refractory SAA or recurrent AA after IST or previously untreated SAA Primary CSR: 2022 Milestone(s) Final CSR: 2025 Hematologic response rate rate up to 26 weeks of treatment Measures Arms Eltrombopag 25 mg film-coated tablets Intervention Target Patients Chinese patients with refractory or relapsed severe aplastic anemia Primary CSR: 2021 Read-out Milestone(s) Interim CSR: 2022 Final CSR:2025 Publication TBD Publication TBD 58 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#59Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars RydaptⓇ - Multi-targeted kinase inhibitor NCT03591510 (CPKC412A2218) Acute myeloid leukemia, pediatrics Phase 2 Indication Phase Patients 20 Primary Outcome Measures Arms Intervention Target Patients Occurrence of dose limiting toxicities Safety and Tolerability Chemotherapy followed by Midostaurin Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia (AML) Read-out Milestone(s) 2026 Publication TBD 59 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#60Pending#61Company overview Financial performance Oncology Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Ophthalmology Neuroscience Respiratory Disease sabatolimab - TIM3 antagonist NCT04150029 STIMULUS-AML1 (CMBG453C12201) Indication Unfit acute myeloid leukaemia Phase 2 Phase Patients 86 Primary Outcome Measures Arms Intervention Incidence of dose limiting toxicities (Safety run-in patients only) Percentage of subjects achieving complete remission (CR) Single arm safety and efficacy study of sabatolimab in combination with azacitidine and venetoclax Target Patients Newly diagnosed adult AML patients who are not suitable for treatment with intensive chemotherapy Read-out Milestone(s) 2023 Publication TBD References Abbreviations Cardio-Renal Global Health Biosimilars 61 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#62Company overview Financial performance Oncology Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Ophthalmology Neuroscience Respiratory Disease Scemblix® - BCR-ABL inhibitor NCT04971226 ASC4FIRST (CABL001J12301) Indication Chronic myeloid leukemia, 1st line Phase 3 Phase Patients 402 Primary Outcome Measures Arms Intervention Major Molecular Response (MMR) at week 48 Arm 1: asciminib 80 mg QD Arm 2: Investigator selected TKI including one of the below treatments: - Imatinib 400 mg QD - Nilotinib 300 mg BID - Dasatinib 100 mg QD - Bosutinib 400 mg QD Patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase 2024 Target Patients Read-out Milestone(s) Publication TBD 62 Investor Relations | Q2 2022 Results References Abbreviations Cardio-Renal Global Health Biosimilars NOVARTIS | Reimagining Medicine#63Pending#64Pending#65Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars Immunology 65 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#66Pending#67Pending#68Pending#69Pending#70Pending#71Pending#72Pending#73Company overview Financial performance Oncology Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Ophthalmology Neuroscience Respiratory Disease remibrutinib - BTK inhibitor NCT04109313 (CLOU064A2201E1) Chronic spontaneous urticaria (CSU) Indication Phase Phase 2 Patients 250 Primary Long-term safety and tolerability Selected dose of LOU064 taken orally twice a day (morning and evening) from day 1 to week 52 Patients with CSU who have participated in preceding studies with LOU064 Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) H2 2022 Publication Primary 2023 References Abbreviations Cardio-Renal Global Health Biosimilars 73 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#74Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars remibrutinib - BTK inhibitor NCT05030311 REMIX-1 (CLOU064A2301) Chronic spontaneous urticaria Indication Phase Phase 3 Patients 450 Primary Outcome Measures Arms Intervention Change from baseline in UAS7 (Scenario 1 with UAS7 as primary efficacy endpoint) Arm 1: LOU064 (blinded) LOU064 (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomized in a 2:1 ratio (arm 1:arm 2). Arm 2: LOU064 placebo (blinded) LOU064 placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally for 28 weeks. Randomized in a 2:1 ratio (arm 1:arm 2). Adult Chronic Spontaneous Urticaria (CSU) patients inadequately controlled by H1-antihistamines Target Patients Read-out Milestone(s) 2024 Publication TBD 74 Investor Relations | Q2 2022 Results remibrutinib - BTK inhibitor NCT05032157 REMIX-2 (CLOU064A2302) Chronic spontaneous urticaria Indication Phase Phase 3 Patients 450 Primary Outcome Measures Arms Intervention Target Patients 1. Change from baseline in UAS7 (Scenario 1 with UAS7 as primary efficacy endpoint) 2. Absolute change in ISS7 an absolute change in HSS7 (Scenario 2 with ISS7 and HSS7 as co-primary efficacy endpoints) Arm 1: LOU064 (blinded) LOU064A (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo) Arm 2: LOU064 placebo (blinded) LOU064A placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo) Adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in comparison to placebo Read-out Milestone(s) Publication 2024 TBD 1 NOVARTIS | Reimagining Medicine#75Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars Ophthalmology 75 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#76Pending#77Pending#78Company overview Financial performance Oncology Immunology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars BeovuⓇ - VEGF Inhibitor NCT04278417 (CRTH258D2301) Diabetic retinopathy Indication Phase Phase 3 Patients 706 Primary Change from Baseline in BCVA Outcome Measures Arms Intervention Arm1: RTH258 (brolucizumab) 6 mg/50uL Arm2: Panretinal photocoagulation laser initial treatment followed with additional PRP treatment as needed Target Patients Patients with proliferative diabetic retinopathy Read-out Milestone(s) 2024 Publication TBD 78 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#79Pending#80Pending#81Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars Neuroscience 81 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#82Pending#83Pending#84Pending#85Company overview Financial performance Oncology Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Ophthalmology Neuroscience Respiratory Disease MIJ821 - NR2B negative allosteric modulator (NAM) NCT04722666 (CMIJ821A12201) Indication Phase Major depressiv disorder with acute suicidal ideation or behavior Phase 2 Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) 195 Change from baseline to 24 hours in the total score of the Montgomery Åsberg Depression Rating Scale (MADRS) MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1 followed by Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 15 and Day 29 MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1 followed by Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 15 and Day 29 Participants who have suicidal ideation with intent 2023 Publication TBD 85 Investor Relations | Q2 2022 Results References Abbreviations Cardio-Renal Global Health Biosimilars NOVARTIS | Reimagining Medicine#86Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars ZolgensmaⓇ - SMN1 gene replacement therapy NCT05089656 STEER (COAV101B12301) Indication Phase Patients Primary Outcome Measures Arms Intervention Spinal muscular atrophy (IT administration) Phase 3 125 1. Change from baseline in Hammersmith functional motor scale - Expanded (HFMSE) total score at the end of follow-up period 1 in treated patients compared to sham controls in the ≥ 2 to < 18 years age group Arm 1: Experimental OAV101. Administered as a single, one-time intrathecal dose Arm 2: Sham Comparator: Sham control. A skin prick in the lumbar region without any medication. Patients Type 2 Spinal Muscular Atrophy (SMA) who are ≥ 2 to < 18 years of age, treatment naive, sitting, and never ambulatory Target Patients Read-out Milestone(s) 2024 Publication TBD 86 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#87Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars Respiratory Disease 87 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#88Company overview Financial performance Oncology Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Ophthalmology Neuroscience Respiratory Disease ecleralimab - TSLP inhibitor NCT04410523 (CCSJ117A12201C) Indication Asthma Phase Phase 2 Patients 625 Primary Outcome Measures Pre-dose FEV1 (Forced Expiratory Volume in 1 second) change from baseline after 12 weeks of treatment. Average change from baseline in pre- dose FEV1 at week 8 & week 12 CSJ117 0.5mg Arms Intervention CSJ117 1mg CSJ117 2 mg Target Patients CSJ117 4 mg CSJ117 8 mg Placebo Asthma patients on background medium or high ICS plus LABA therapy Read-out Milestone(s) 2023 Publication Primary publications planned for 2024 88 Investor Relations | Q2 2022 Results References Abbreviations Cardio-Renal Global Health Biosimilars NOVARTIS | Reimagining Medicine#89Company overview Financial performance Oncology Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Ophthalmology Neuroscience Respiratory Disease icenticaftor - CFTR potentiator NCT04072887 (CQBW251B2201) Chronic obstructive pulmonary disease Indication Phase Phase 2 Patients 956 Primary Outcome Measures Arms QBW251 450 mg Intervention QBW251 300 mg Trough FEV1 (Forced Expiratory Volume in 1 second) change from baseline after 12 weeks of treatment Target Patients QBW251 150 mg QBW251 75 mg QBW251 25 mg Placebo COPD patients on background triple inhaled therapy (LABA / LAMA / ICS) Read-out Milestone(s) Q2-2022 (actual) Publication Primary publications planned H2 2022 89 Investor Relations | Q2 2022 Results References Abbreviations Cardio-Renal Global Health Biosimilars NOVARTIS | Reimagining Medicine#90Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars Cardio-Renal 90 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#91Pending#92Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars EntrestoⓇ - Angiotensin receptor/neprilysin inhibitor NCT03785405 (CLCZ696B2319E1 - extension study) Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Heart failure in pediatric patients Phase 3 240 Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Single arm, open label sacubitril/valsartan (pediatric formulation granules (12.5, 31.25 mg in capsules); liquid formulation (1mg/ml and 4mg/ml concentration) and adult formulation (50, 100, 200 mg bid)) Pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who have completed study CLCZ696B2319 2023 Read-out Milestone(s) Publication TBD 92 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#93Pending#94Pending#95Pending#96Pending#97Company overview Financial performance Oncology Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Ophthalmology Neuroscience Respiratory Disease Leqvio® - siRNA (regulation of LDL-C) References Abbreviations Cardio-Renal Global Health Biosimilars LeqvioⓇ - siRNA (regulation of LDL-C) NCT03851705 ORION-5 (CKJX839A12302) Hypercholesterolemia inc. Homozygous Familial Hypercholesterolemia (HoFH) Phase 3 NCT03814187 ORION-8 (CKJX839A12305B) Indication Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia (HeFH) and Homozygous Familial Hypercholesterolemia (HoFH) Phase 3 Indication Phase Phase Patients 3275 Primary Outcome Measures Arms Intervention Target Patients Proportion of subjects achieving prespecified low density lipoprotein cholesterol (LDL-C) targets at end of study Safety and tolerability profile of long term use of inclisiran Inclisiran sodium 300mg on Day 90 and every 180 days for a planned duration of 3 years Patients with HeFH or pre-existing atherosclerotic cardiovascular disease (ASCVD) on background statin +/- ezetimibe therapy and risk equivalents (patients from ORION 3, 9, 10 & 11 studies) LDL-C reduction at Day 150 Patients 56 Primary Outcome Measures Arms Intervention Target Patients Changes in PCSK9, other lipids and lipoproteins Part 1: inclisiran sodium 300mg or placebo on Day 1 and Day 90 Part 2: inclisiran sodium 300mg on Day 180 for patients who were randomized to the placebo group only, inclisiran sodium 300mg on Day 270 and then every 6 months for a planned duration of 2 years for all patients Patients with HoFH with background statin +/- ezetimibe therapy Read-out Milestone(s) 2023 Publication TBD 97 Investor Relations | Q2 2022 Results Read-out Milestone(s) Publication Q1-2022 (actual) TBD NOVARTIS | Reimagining Medicine#98Pending#99Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars pelacarsen - ASO targeting Lp(a) NCT04023552 Lp(a)HORIZON (CTQJ230A12301) Indication Cardiovascular risk reduction Phase Phase 3 Patients 8350 Primary Outcome Measures Arms Intervention Target Patients Time to the first occurrence of MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization) TQJ230 80 mg injected monthly subcutaneously or matched placebo Patients with a history of Myocardial infarction or Ischemic Stroke, or a clinically significant symptomatic Peripheral Artery Disease, and Lp(a) ≥ 70 mg/dL Read-out Milestone(s) 2025 Publication TBD 99 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#100Pending#101Company overview Financial performance Oncology Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Ophthalmology Neuroscience Respiratory Disease Adakveo® - P-selectin inhibitor NCT03474965 SOLACE-Kids (CSEG101B2201) Indication Phase Patients Primary Outcome Measures Arms Sickle cell disease, pediatrics Phase 2 100 PK/PD and safety of SEG101 at 5 mg/kg Intervention Target Patients Read-out Milestone(s) Publication SEG101 (crizanlizumab) at a dose of 5 mg/kg by IV infusion + Hydroxyurea/Hydroxycarbamide Pediatric SCD patients with VOC H2-2021 (pediatric patients ≥12 year old) 2024 (pediatric patients <12 year old) 1. Matthew M. Heeney, David C. Rees, Mariane de Montalembert, Isaac Odame, R. Clark Brown, Yasser Wali, Thu Thuy Nguyen, Du Lam, Raquel Merino Herranz, Julie Kanter; Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease. Blood 2020; 136 (Supplement 1): 22-24. doi: https://doi.org/10.1182/blood-2020-137081 2. Matthew M. Heeney, David C. Rees, Mariane De Montalembert, Isaac Odame, R. Clark Clark Brown, Yasser Wali, Thu Thuy Nguyen, Du Lam, Nadege Pfender, Julie Kanter; Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD). Blood 2021; 138 (Supplement 1): 12. doi: https://doi.org/10.1182/blood-2021-144730 101 Investor Relations | Q2 2022 Results References Abbreviations Cardio-Renal Global Health Biosimilars NOVARTIS | Reimagining Medicine#102Pending#103Pending#104Pending#105Company overview Financial performance Oncology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Immunology Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars aflibercept - VEGF inhibitor NCT04864834 Mylight (CSOK583A12301) Indication Ophthalmology indication (as originator) Phase Phase 3 Patients 460 Primary Outcome Measures Arms Intervention Target Patients Best-corrected visual acuity (BCVA) will be assessed using the ETDRS testing charts at an initial distance of 4 meters. The change from baseline in BCVA in letters is defined as difference between BCVA score between week 8 and baseline Arm 1 Biological: SOK583A1 (40 mg/mL) Arm 2 Biological: Eylea EU (40 mg/mL) Patients with neovascular age-related macular degeneration Read-out 2023 Milestone(s) Publication tbd 105 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#106Company overview Financial performance Oncology Immunology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars denosumab - anti RANKL mAb NCT03974100 (CGP24112301) Osteoporosis (same as originator) Indication Phase Phase 3 Patients 522 Primary Outcome Measures Arms Percent change from baseline (%CfB) in lumbar spine Bone Mineral Density Intervention GP2411 60 mg/mL subcutaneous injection every 6 months ProliaⓇ 60 mg/mL subcutaneous injection every 6 months Postmenopausal women with osteoporosis Target Patients Read-out Milestone(s) Publication 2022 Study data publications expected for 2024 and beyond. The overall study design will be published at WCO and ECTS congresses 2020. 106 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine#107Pending#108Pending